Apogee Therapeutics Aktie: J&J-Flop öffnet Tür für APG279

New York (www.aktiencheck.de) - Apogee Therapeutics-Aktienanalyse von BTIG:Die Analysten von BTIG haben das "buy"-Rating für die Aktie von Apogee Therapeutics Inc. (ISIN: US03770N1019, WKN: A3EM1H, NASDAQ-Symbol: APGE) bestätigt und das Kursziel bei 115 USD belassen.Nach der jüngsten Mitteilung von Johnson & Johnson (JNJ), wonach die Phase-2b-DUPLEX-AD-Studie zum Wirkstoff JNJ-95475939 zur Behandlung von mittelschwerer bis schwerer atopischer Dermatitis die Wirksamkeitserwartungen nicht erfü...

Wall Street Analysts See a 152.41% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 152.4% in Apogee Therapeutics Inc. (APGE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer

ROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ: SUPN) ("Supernus", and the "Company"), today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"), with respect to Supernus’ proposed acquisition of Sage Therapeutics, Inc., a Delaware corporation (NASDAQ: SAGE) ("Sage"), expired at 11:59 p.m. Eastern Time on July 25, 2025.

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal

SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.

Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock?

Sage Therapeutics (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesnt suggest further strength down the road.

Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus

Stock market futures are up slightly. Enthusiasm has been tempered by geopolitical risks and uncertainty ahead of Wednesday’s Federal Reserve decision. The Fed is widely expected to hold rates steady, but investors are laser-focused on Chair Powell’s language regarding potential rate cuts later this year. Currently, markets are pricing in a roughly 56% chance of a quarter-point cut by September. In the background, rising tensions between Israel and Iran continue to cast a long shadow. Oil prices

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

ROCKVILLE, Md. and CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Sage Therapeutics, Inc. (Nasdaq: SAGE), today announced a definitive agreement for Supernus to acquire Sage through a tender offer for $8.50 per share in cash (or an aggregate of approximately $561 million), payable at closing, plus one non-tradable contingent value right (CVR) collectively worth up to $3.50 per share in cash (or an aggregate of approximately $234 million), ...

Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 129.1% in Apogee Therapeutics Inc. (APGE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Why Is Sage Therapeutics (SAGE) Down 11.1% Since Last Earnings Report?

Sage Therapeutics (SAGE) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for some clues.

Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet

The consensus price target hints at a 132.7% upside potential for Apogee Therapeutics Inc. (APGE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 134%: Heres is How to Trade

The mean of analysts price targets for Apogee Therapeutics Inc. (APGE) points to a 134% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Sage Therapeutics Q1 Earnings Miss Mark, Revenue Rise Y/Y

SAGEs earnings and revenues miss estimates in the first quarter of 2025. The company focuses on the commercialization of its depression drug Zurzuvae.

Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue Estimates

Sage Therapeutics (SAGE) delivered earnings and revenue surprises of -2.02% and 0.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Weeks Release

Sage Therapeutics (SAGE) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sage Therapeutics: A Speculative Play That Needs To Wait For A Turnaround Story

Sage Therapeutics: Biogens $7.22/Share Bid Might Say More Than The Price Tag

Sage Therapeutics (SAGE) Up 7.4% Since Last Earnings Report: Can It Continue?

Sage Therapeutics (SAGE) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for some clues.

Sage Therapeutics Q4 Earnings Miss Mark, Revenues Plunge Y/Y

SAGEs earnings and revenues miss estimates in the fourth quarter of 2024. The company focuses on the commercialization of depression drug Zurzuvae.

Sage Therapeutics, Inc. (SAGE) Q4 2024 Earnings Call Transcript

Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Lags Revenue Estimates

Sage Therapeutics (SAGE) delivered earnings and revenue surprises of -7.59% and 11.20%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out for

Sage Therapeutics (SAGE) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Key deals this week: Molson Coors Beverage, Emerson Electric, Sage Therapeutics and more

SAGE Rejects Biogens Offer to Buy Remaining Stake, Stock Up

Sage Therapeutics turns down Biogens offer to buy the remaining stake in the company and is evaluating strategic alternatives to maximize shareholder value.

Sage Therapeutics: Biogens Unsolicited Bid Is Best Step Forward For Shareholders

Sage Therapeutics Jumps on Biogen’s $469 Million Offer

Shares of Sage Therapeutics Inc. surged after Biogen Inc. offered to acquire the neuroscience-focused drugmaker for about $469 million.

Sage Therapeutics shares surge on unsolicited takeover bid from Biogen

Sage Therapeutics (NASDAQ:SAGE) stock soared after the firm announced that it had received an unsolicited takeover bid from Biogen Inc (NASDAQ:BIIB,...

Biogen Offers to Buy Remaining Stake in Sage Therapeutics

Biogen offers to buy the remaining stake in Sage Therapeutics for $7.22 per share. SAGE stock rises.

Biogen Aktie: Positive Resonanz auf Neues!

Der US-Biotechnologiekonzern Biogen plant einen strategischen Schritt zur Erweiterung seines Portfolios. Das Unternehmen hat ein Angebot zur Übernahme der verbleibenden Anteile an Sage Therapeutics...

Biogen proposes to buy remaining stake in Sage in $442 million deal

Drugmaker Biogen will buy all outstanding shares of Sage Therapeutics that it does not already own for $7.22 apiece, a filing showed on Friday, sending the latters stock up 34% in extended trade.

SAGEs Dalzanemdor Fails to Meet Goal in Huntingtons Disease Study

Sage Therapeutics pipeline setbacks continue as the phase II DIMENSION study on dalzanemdor for treating Huntingtons disease fails to meet the primary goal.